BSTC:OTC-BioSpecifics Technologies Corp (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 0.00

Change

0.00 (0.00)%

Market Cap

USD 0.65B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

BSTC Stock Forecast & Price:
Based on the BioSpecifics Technologies Corp stock forecasts from 0 analysts, the average analyst target price for BioSpecifics Technologies Corp is not available over the next 12 months. BioSpecifics Technologies Corp’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of BioSpecifics Technologies Corp is Very Bullish, which is based on 2 positive signals and 0 negative signals. At the last closing, BioSpecifics Technologies Corp’s stock price was USD 0.00. BioSpecifics Technologies Corp’s stock price has changed by 0% over the past week, 0% over the past month and 0% over the last year.

No recent analyst target price found for BioSpecifics Technologies Corp
No recent average analyst rating found for BioSpecifics Technologies Corp

About BioSpecifics Technologies Corp (BSTC:OTC)

BioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and P ...Read More

Company Website : http://www.biospecifics.com

Address : Delaware Corporate Center II, Wilmington, DE, United States, 19803

Employees : 7

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.24

Short Ratio : 0.34

Shorted Shares : 74,067

200 Day Moving Average : 70.09

Shorted Shares Previous Month : 60,464

50 Day Moving Average : 88.50

Shares Held By Insiders : 18.64%

Short Percentage : 1.19%

Shares Held by Institutions : 66.48%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

N/A

 USD221.74B 32.73 3.07
AKABY ALK-Abello A/S ADR

N/A

 USD99.09B 3,000.00 6.56
CMXHF CSL Limited

N/A

 USD91.61B 38.96 26.37
CSLLY CSL Ltd

N/A

 USD88.51B 37.71 26.37
WXXWY WuXi Biologics (Cayman) Inc

N/A

 USD25.98B 54.91 5.95
WXIBF WuXi Biologics

N/A

 USD25.79B 55.45 5.95
GNMSF Genmab A/S

N/A

 USD21.60B 40.37 3.93
ARGNF argenx SE

N/A

 USD20.91B N/A -20.54
SHJBF Shanghai Junshi Biosciences Co..

N/A

 USD13.48B N/A -16.40
UCBJY UCB SA ADR

N/A

 USD13.12B 14.73 9.76

ETFs Containing BSTC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 10.85% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.85% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 23.94% N/A N/A N/A N/A
Risk Adjusted Return 45.31% N/A N/A N/A N/A
Market Capitalization 0.65B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 37.51 N/A N/A N/A N/A
Price/Book Ratio 4.81 N/A N/A N/A N/A
Price / Cash Flow Ratio 29.18 N/A N/A N/A N/A
EV/EBITDA 25.95 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 20.25% N/A N/A N/A N/A
Return on Assets 11.58% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 0.34 N/A N/A N/A N/A
Short Percent 1.19% N/A N/A N/A N/A
Beta 0.24 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment
Stock Target Advisor

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike